In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

At the April Sampson Cancer Center on Monday, Tom Uhlman shared his story as part of the Shine a Light on Lung Cancer ...

Metropolis molecular genomics study shows genetic profiling are improving survival rates: Our Bureau, Bengaluru Friday, November 22, 2024, 14:45 Hrs [IST] Metropolis Healthcare co ...

Louisiana residents have one of the highest lung cancer death rates in the country, even as groundbreaking treatments in ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced ... demonstrated better ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...

Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.

Advances in genetic profiling are now helping improve survival rates by allowing treatment plans ... focusing on key genes ...

Immutep (IMMP) has released an update. Immutep has announced encouraging results from its INSIGHT-003 trial, showing that their drug ...